Detalhe da pesquisa
1.
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
Oncologist
; 26(3): 184-e366, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33458921
2.
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
Blood
; 134(17): 1395-1405, 2019 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31471376
3.
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Blood
; 131(4): 397-407, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29141948
4.
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Blood
; 132(1): 40-48, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703778
5.
Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials.
Hematol Oncol
; 38(1): 51-58, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31872891
6.
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.
Haematologica
; 104(5): 993-1003, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573506
7.
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
Lancet Oncol
; 19(2): 257-266, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29276022
8.
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
Br J Haematol
; 177(2): 243-253, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28220479
9.
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
Br J Haematol
; 189(3): e86-e90, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32048731
10.
Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.
Front Pharmacol
; 15: 1223858, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344177
11.
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Leuk Lymphoma
; 65(6): 736-745, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517235
12.
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Br J Haematol
; 180(5): 757-760, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27984643
13.
RWD-derived response in multiple myeloma.
PLoS One
; 18(5): e0285125, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37167221
14.
New therapeutic targets and drugs in non-Hodgkin's lymphoma.
Curr Opin Hematol
; 18(4): 280-7, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21654386
15.
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Clin Cancer Res
; 27(8): 2190-2199, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451977
16.
ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest.
Oncotarget
; 11(37): 3432-3442, 2020 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32973968
17.
Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series.
Ther Adv Hematol
; 11: 2040620720947340, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33062232
18.
Clinical Characteristics and Outcomes of Caribbean Patients With Adult T-Cell Lymphoma/Leukemia at Two Affiliated New York City Hospitals.
JCO Glob Oncol
; 6: 548-556, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32243210
19.
Endometriosis in the rectus abdominis muscle: case report and literature review.
J La State Med Soc
; 161(6): 321-4, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-20108826
20.
Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL.
Front Oncol
; 9: 645, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31417860